Vol. 12. Núm. 23.
Páginas 1337-1349 (Diciembre 2016)

Actualización
Tratamiento de las enfermedades desmielinizantes. Esclerosis múltiple

Treatment of demyelinating diseases. Multiple sclerosis

M. Díaz SánchezM.D. Jiménez Hernández
Doi : https://10.1016/j.med.2016.12.003
Opciones
Resumen
Introducción

Las enfermedades desmielinizantes del sistema nervioso central (SNC) constituyen un grupo heterogéneo de enfermedades autoinmunes en las que se desarrolla un daño de la mielina. De todas ellas, la esclerosis múltiple (EM) es la más prevalente, siendo la causa más frecuente de discapacidad neurológica crónica no traumática en adultos jóvenes y de mediana edad. Por este motivo, su adecuado manejo terapéutico, desde fases iniciales de la enfermedad, es esencial.

Resultados

El manejo terapéutico de la EM incluye tanto la búsqueda del control de su actividad clínica y radiológica, como el tratamiento sintomático y rehabilitador de sus complicaciones y/o secuelas. En esta actualización se revisarán los tratamientos de las reagudizaciones, y en especial los fármacos modificadores de la enfermedad, sus indicaciones según escenario de la enfermedad, posología, efectos adversos, interacciones y criterios de sustitución.

Conclusión

Actualmente se dispone de un amplio arsenal terapéutico para el tratamiento de la EM, con fármacos capaces de modificar el curso de esta enfermedad, lo que ha supuesto un cambio importante en la historia natural de esta patología. El uso precoz de estos tratamientos es un factor esencial para mejorar el pronóstico de los pacientes con EM.

Palabras clave
Esclerosis múltiple
Tratamiento modificador de la enfermedad
Brotes
Desarrollo de discapacidad
Abstract
Introduction

Demyelinating diseases of the central nervous system (CNS) constitute a heterogeneous group of autoimmune diseases in which myelin damage develops. Of these, multiple sclerosis (MS) is the most prevalent, being the most frequent cause of chronic non-traumatic neurological disability in young and middle-aged adults. For this reason, its adequate therapeutic management, from the early stages of the disease, is essential.

Results

The therapeutic management of MS includes both the search for control of its clinical and radiological activity, as well as the symptomatic and rehabilitative treatment of its complications and / or sequelae. This update will review treatments for exacerbations, and especially disease-modifying drugs, their indications according to disease scenario, dosage, adverse effects, interactions and substitution criteria.

Conclusion

Currently there is a wide therapeutic arsenal for the treatment of MS, with drugs capable of modifying the course of this disease, which has meant a significant change in the natural history of this pathology. The early use of these treatments is an essential factor to improve the prognosis of patients with MS.

Keywords
Multiple sclerosis
Disease modifying treatment
Relapses
Development of disability

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
201612170118004208
201612170118004209
W.J. Brownlee, D.H. Miller.
Clinically isolated syndromes and the relationship to multiple sclerosis.
J Clin Neurosci., (2014), 21 pp. 2065-2071
[2]
2016121701180042010
2016121701180042011
W.I. McDonald, A. Compston, G. Edan, D. Goodkin, H.P. Hartung, F.D. Lublin, et al.
Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.
Ann Neurol., (2001), 50 pp. 121-127
[3]
2016121701180042012
2016121701180042013
J.H. Noseworthy, C. Lucchinetti, M. Rodríguez, B.G. Weinshenker.
Multiple sclerosis.
N Engl J Med., (2000), 343 pp. 938-952
[4]
2016121701180042014
D.J. Costello, A.F. Eichler, F.S. Eichler.
Leukodystrophies: classification, diagnosis, and treatment.
Neurologist., (2009), 15 pp. 319-328
[5]
2016121701180042015
A.P. Sempere, L.E. Clavería, J. Duarte, F. Coria, C. Cabezas.
Multiple sclerosis in Spain.
Neurology., (1995), 45 pp. 202
[6]
2016121701180042016
2016121701180042017
F.D. Lublin, S.C. Reingold.
Defining the clinical course of multiple sclerosis: results of an international survey.
Neurology., (1996), 46 pp. 907-911
[7]
2016121701180042018
2016121701180042019
M. Filippi, M.A. Rocca, O. Ciccarelli, N. De Stefano, N. Evangelou, L. Kappos, et al.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Lancet Neurol., (2016), 15 pp. 293-303
[8]
2016121701180042020
T. Kuhlmann, G. Lingfeld, A. Bitsch, J. Schuchardt, W. Bruck.
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.
Brain., (2002), 125 pp. 2202-2212
[9]
2016121701180042021
2016121701180042022
M.S. Freedman, G. Comi, N. De Stefano, F. Barkhof, C.H. Polman, B.M. Uitdehaag, et al.
Moving toward earlier tretament of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice.
Mult Scler Relat Disord., (2014), 3 pp. 147-155
[10]
2016121701180042023
2016121701180042024
G. Giovannoni, B. Turner, S. Gnanapavan, C. Offiah, K. Schmierer, M. Marta.
Is I time to target no evident disease activity (NEDA) in multiple sclerosis?.
Mult Scler Relat Dosord., (2015), 4 pp. 329-333
[11]
2016121701180042025
2016121701180042026
R.R. Berkovich.
Acute multiple sclerosis relapse.
Continuum., (2016), 22 pp. 799-814
[12]
2016121701180042027
E. Le Page, D. Veillard, D.A. Laplaud, S. Hamonic, R. Wardi, C. Lebrun, et al.
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Lancet., (2015), 386 pp. 974-981
[13]
2016121701180042028
M. Keegan, A.A. Pineda, R.L. McClelland, C.H. Darby, M. Rodriguez, B.G. Weinshenker.
Plasma exchange for severe attacks of CNS demyelination: predictors of response.
Neurology., (2002), 58 pp. 143-146
[14]
2016121701180042029
The INFβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-61.
[15]
2016121701180042030
L.D. Jacobs, R.W. Beck, J.H. Simon, R. Phillip Kinkel, C.M. Brownscheidle, T.J. Murray, et al.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
N Engl J Med, (2000), 343 pp. 898-904
[16]
2016121701180042031
G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edam, O. Fernández, et al.
Effect of early interferon treatment on conversion to definite multiple sclerosis.
Lancet., (2001), 357 pp. 1576-1582
[17]
2016121701180042032
L. Kappos, C.H. Polman, M.S. Freedman, G. Edan, H.P. Hartung, D.H. Miller, et al.
Treatment with interferon beta-1b delays conversion to clinically definite MS in patients with clinically isolated syndromes.
Neurology., (2006), 67 pp. 1242-1249
[18]
2016121701180042033
G. Comi, V. Martinelli, M. Rodegher, L. Moiola, O. Bajenaru, A. Carra, et al.
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndromes (PreCISe): a randomised, double-blind, placebo-controlled trial.
Lancet., (2009), 374 pp. 1503-1511
[19]
2016121701180042034
2016121701180042035
F.D. Lublin, S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sorensen, A.J. Thompson, et al.
Defining the clinical course of multiple sclerosis.
The 2013 revision Neurology., (2014), 83 pp. 1-9
[20]
2016121701180042036
2016121701180042037
C.H. Polman, S. Reingold, B. Banwell, M. Clanet, J.A. Cohen, M. Filippi, et al.
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Ann Neurol., (2011), 69 pp. 292-302
[21]
2016121701180042038
K.P. Johnson, B.R. Brooks, J.A. Cohen, C.C. Ford, J. Goldstein, R.P. Lisak, The Copolymer 1 Multiple Sclerosis Study Group, et al.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial.
Neurology, (1995), 45 pp. 1268-1276
[22]
2016121701180042039
L.D. Jacobs, D.L. Cookfair, R.A. Rudick, R.A. Herndon, J.R. Richert, A.M. Salazar, et al.
Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis.
Ann Neurol., (1996), 39 pp. 285-294
[23]
2016121701180042040
PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group.
Randomized double blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.
Lancet, (1998), 352 pp. 1498-1504
[24]
2016121701180042041
P. O’Connor, J.S. Wolinsky, C. Confavreux, G. Comi, L. Kappos, T.E. Olsson, et al.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
N Engl J Med., (2011), 365 pp. 1293-1303
[25]
2016121701180042042
R. Gold, L. Kappos, D.L. Arnold, A. Bar-Or, G. Giovannoni, K. Selmaj, et al.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
N Engl J Med., (2012), 367 pp. 1098-1107
[26]
2016121701180042043
P.A. Calabresi, B.C. Kieseier, D.L. Arnold, L.J. Balcer, A. Boyko, J. Pelletier, et al.
Pegylated interferon-β 1ª for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, doublé-blind study.
Lancet Neurol., (2014), 13 pp. 657-665
[27]
2016121701180042044
I. Casseta, G. Iuliano, G. Filippini.
Azathioprine for multiple sclerosis.
Cochrane Database Syst Rev., (2007), 4 pp. CD003982
[28]
2016121701180042045
H.P. Hartung, R. Gonsett, N. Konig, H. Kwiecinski, A. Guseo, P. Morrisey, et al.
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized multicentre trial.
Lancet., (2002), 360 pp. 2018-2025
[29]
2016121701180042046
C.H. Polman, P.W. O’Connor, E. Harvrdova, M. Hutchinson, L. Kappos, D.H. Miller, et al.
A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med., (2006), 354 pp. 899-910
[30]
2016121701180042047
L. Kappos, E.W. Radue, P. O’Connor, C.H. Polman, R. Hohfled, P. Calabresi, et al.
A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis.
N Engl J Med., (2010), 365 pp. 1293-1303
[31]
2016121701180042048
A.J. Coles, C.L. Twyman, D.L. Arnold, J.A. Cohen, C. Confavreux, E.J. Fox, et al.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Lancet., (2012), 380 pp. 1829-1839
[32]
2016121701180042049
A.E. Miller, J.R. Wolinsky, L. Kappos, G. Comi, M.S. Freedman, T.P. Olsson, et al.
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC); a randomized double-blind, placebo-controlled, phase 3 trial.
Lancet Neurol., (2014), 13 pp. 977-986
[33]
2016121701180042050
European Study Group on interferon beta-1b in secondary progressive MS.
Placebo-controlled multicentre randomised trial of interferon beta 1b in treatment of secondary progressive multiple sclerosis.
Lancet., (1998), 352 pp. 1491-1497
[34]
2016121701180042051
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS(SPECTRIMS) Study Group.
Randomized controlled trial of interferón-beta-1ª in secondary progressive MS: clinical results.
Neurology., (2001), 56 pp. 1496-1504
[35]
2016121701180042052
P.S. Sorensen, M. Blinkenberg.
The potential rote for ocrelizumab in the traetment of multiple sclerosis: current evidence and future prospects.
Ther Adv Neurol Disord., (2016), 9 pp. 44-52
[36]
2016121701180042053
2016121701180042054
J. Río, C. Nos, M. Tintoré, N. Téllez, I. Galán, R. Pelayo, et al.
Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Ann Neurol., (2006), 59 pp. 344-352
[37]
2016121701180042055
2016121701180042056
P. Rieckmann.
Concepts of induction and escalation therapy in multiple sclerosis.
J Neurol Sci., (2009), 277 pp. S42-S45
[38]
2016121701180042057
2016121701180042058
O. Fernández, J.A. García Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, et al.
Consenso español actualizadosobre el uso de natalizumab (Tysabri®)-2013.
Neurología., (2015), 30 pp. 302-314